Avalo Therapeutics Ownership
| AVTX Stock | USD 7.66 0.56 6.81% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 7.7 M | Current Value 10.8 M | Avarage Shares Outstanding 903 K | Quarterly Volatility 2.4 M |
Avalo |
Avalo Stock Ownership Analysis
About 73.0% of the company shares are held by institutions such as insurance companies. The book value of Avalo Therapeutics was presently reported as 2.18. The company recorded earning per share (EPS) of 94.42. Avalo Therapeutics had not issued any dividends in recent years. The entity had 1:240 split on the 29th of December 2023. Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. Cerecor operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 42 people. For more info on Avalo Therapeutics please contact the company at 410 522 8707 or go to https://www.avalotx.com.Besides selling stocks to institutional investors, Avalo Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Avalo Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Avalo Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Avalo Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Avalo Therapeutics Insider Trades History
About 6.0% of Avalo Therapeutics are currently held by insiders. Unlike Avalo Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Avalo Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Avalo Therapeutics' insider trades
Avalo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Avalo Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Avalo Therapeutics backward and forwards among themselves. Avalo Therapeutics' institutional investor refers to the entity that pools money to purchase Avalo Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Royal Bank Of Canada | 2024-12-31 | 117.4 K | Velan Capital Investment Management Lp | 2024-12-31 | 110 K | Geode Capital Management, Llc | 2024-12-31 | 104.9 K | Ubs Group Ag | 2024-12-31 | 98.5 K | Allostery Investments Lp | 2024-12-31 | 73.3 K | Sio Capital Management, Llc | 2024-12-31 | 71.5 K | Bank Of Montreal | 2024-12-31 | 60 K | Bmo Capital Markets Corp. | 2024-12-31 | 60 K | Hrt Financial Llc | 2024-12-31 | 40 K | Bvf Inc | 2024-12-31 | 1 M | Ikarian Capital, Llc | 2024-12-31 | 970.3 K |
Avalo Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Avalo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Avalo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Avalo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Avalo Therapeutics Outstanding Bonds
Avalo Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Avalo Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Avalo bonds can be classified according to their maturity, which is the date when Avalo Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| AZO 475 01 AUG 32 Corp BondUS053332BB79 | View | |
| AZO 45 01 FEB 28 Corp BondUS053332BC52 | View | |
| US053332BA96 Corp BondUS053332BA96 | View | |
| AZO 475 01 FEB 33 Corp BondUS053332BD36 | View | |
| US053332AY81 Corp BondUS053332AY81 | View | |
| AUTOZONE INC Corp BondUS053332AZ56 | View | |
| AUTOZONE INC 375 Corp BondUS053332AV43 | View |
Avalo Therapeutics Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 30th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 3rd of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.